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Background: Organizing pneumonia (OP) is a distinct histopathologic lesion that
occurs in a variety of clinical contexts. There have been occasional reports of OP
occurring in patients with hematologic malignancies.
Study objectives: To examine the association of OP with hematologic malignancies
and to assess the clinical course of affected patients.
Design: A retrospective review of our institutional experience of unexplained OP
developing in patients with hematologic malignancies.
Setting: Tertiary care, referral medical center.
Patients: We identified 6 patients with a verified histopathologic diagnosis of OP and
antecedent or concomitant diagnosis of a hematologic malignancy from the Mayo
Clinic database (1995–2003). Clinical, radiologic, and outcome data were abstracted
from records.
Results: Underlying hematologic disorders included lymphoma (2), acute leukemia
(2), cutaneous T-cell lymphoma (1), and myelodysplastic syndrome (1). OP was
diagnosed by surgical lung biopsy in 4 and bronchoscopic biopsy in 2. Four of the 6
patients had previously been exposed to chemotherapeutic agents, two had not.
Three of the 6 patients had bone marrow transplantation prior to development of OP.
Five patients were treated with prednisone and all experienced symptomaticElsevier Ltd. All rights reserved.
tic leukemia; AML, acute myelogenous leukemia; BMT, bone marrow transplantation; BOOP,
umonia; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; CT,
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OP in hematologic malignancies 163improvement with documented radiologic resolution in 4. One patient experienced
symptomatic and radiologic resolution with observation alone. Three patients
ultimately died from complications of their underlying hematologic disorder and 1
patient died of unknown causes. Two patients were alive without respiratory
complaints more than 1 year after lung biopsy.
Conclusions: OP occurs in patients with underlying hematologic malignancies who
may or may not have been treated with chemotherapy and responds favorably to
corticosteroid therapy.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Organizing pneumonia (OP) is a distinctive histo-
pathologic pattern that can be encountered in
a variety of clinical contexts. In some patients,
it may represent a relatively non-specific repara-
tive process associated with another primary
pathologic condition such as infection, infarction,
carcinoma, and Wegener’s granulomatosis.1 In
other patients OP may be the primary pathologic
process. Cryptogenic OP (COP) refers to OP that
occurs without an identifiable cause or associated
disease, e.g., connective tissue disease. Not
surprisingly, OP has also been reported in patients
with hematologic malignancies.2–4 Potential etiol-
ogies for OP in patients with hematologic malig-
nancies include infection, radiation and
chemotherapy. OP has also been described as a
non-infectious complication of bone marrow trans-
plantation (BMT).2 More recently, hematologic
malignancy itself has been implicated as a potential
risk factor for OP.3,4
Pulmonary infiltrates in patients with hematolo-
gic malignancy are common and result from varied
etiologies including infection, pulmonary edema,
hemorrhage, and underlying malignancy.5,6 OP
unrelated to infection or any other identifiable
cause, has been described in patients with hema-
tologic malignancies. The clinical presentation of
OP is difficult to distinguish from other pathologic
processes and mimics that of respiratory infection
with fever, dyspnea, cough, and malaise as the
dominant symptoms.7 Radiologic abnormalities are
also non-specific with patchy consolidation and
‘‘ground glass’’ opacities.3,7
It is important to distinguish OP from
other causes of pulmonary infiltrates in patients
with hematologic malignancies because this
pulmonary reaction appears to responds to
corticosteroid therapy.4,8 In this study, we exam-
ined our experience with OP in patients with
hematologic malignancy to clarify this association
and to assess the clinical course of these
patients.Patients and methods
Patients with a histopathological diagnosis of OP or
(bronchiolitis obliterans organizing pneumonia
[BOOP]) on a surgical or bronchoscopic lung biopsy
and antecedent or concomitant diagnosis of a
hematologic malignancy who were seen at the
Mayo Clinic in Rochester, MN, from January 1, 1995,
to December 31, 2003, were eligible for the study.
We identified 17,808 unique patients with an
antecedent or concomitant diagnosis of a hemato-
logic malignancy and 11 of these had a correspond-
ing histopathological diagnosis of OP. All lung
biopsies were reviewed by one of us (JLM). OP
was considered a secondary histopathologic finding
in 5 patients leaving 6 in whom OP was the primary
pathologic process without an identifiable cause,
e.g., infection. These 6 patients comprise the
study group.
The following data were abstracted from the
clinical records: age, sex, smoking history, vital
status, physical examination and laboratory find-
ings, findings on chest radiography and computed
tomography (CT), prescribed treatment, follow-up
information, and cancer information, including
diagnosis and date of diagnosis, chemotherapeutic
regimen, BMT, radiation therapy, complications of
therapy, and graft-vs.-host disease (GVHD).
This study was approved by the Mayo Foundation
Institutional Review Board. Data are presented as
mean7SD, median, and range for continuous vari-
ables and frequency and percentage for categorical
variables.Results
Patient characteristics
Table 1 outlines the demographic and clinical
features of 6 patients with unexplained OP and an
antecedent or concomitant diagnosis of hematolo-
gic malignancy who were seen at Mayo Clinic,
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C.E. Daniels et al.164Rochester, MN from 1995 through 2003. Four were
men and the mean age at diagnosis was 52 years
(range, 31–73 years). Four were never smokers and
2 were current smokers with 45 and 30 accumu-
lated pack-years of cigarette smoking, respec-
tively. All patients had a preceding diagnosis of
hematologic malignancy and included 3 patients
with lymphomas (Hodgkin’s lymphoma, B-cell lym-
phoma, and cutaneous T-cell lymphoma/Se´zary
syndrome), 2 patients with leukemias (acute
myelogenous leukemia [AML] and acute lymphocy-
tic leukemia), and 1 patient with myelodysplastic
syndrome (MDS) at the time of OP diagnosis who
developed AML 5 months later. Four patients had
received chemotherapy prior to the development
of respiratory complaints. The chemotherapeutic
agents included cyclophosphamide (4 patients),
etoposide (3 patients), doxorubicin (2 patients),
and vincristine (2 patients). In addition, bleomycin,
carmustine, cytarabine, mechlorethamine, metho-
trexate, procarbazine, and vinblastine had been
administered to 1 patient each. The mean interval
from last exposure to chemotherapy and the
histopathologic recognition of OP was 7 months
(range, 0–12 months). Two patients had a history of
prior radiation therapy; both 1 year prior to
diagnosis of OP. Three patients had previously
undergone BMT (2 allogeneic and 1 autologous) at
2, 4, and 24 months prior to diagnosis of OP.Clinical presentation and diagnosis
Five patients had respiratory or constitutional
symptoms at presentation; cough and dyspnea
were the presenting complaints in 3. Fatigue (3
patients) and fever (3 patients) were also noted. No
patient had a history of chest pain or hemoptysis
prior to presentation. One asymptomatic patient
had a normal cardiopulmonary examination and
was noted to have diffuse infiltrate on surveillance
CT scan of the chest. In all symptomatic patients,
inspiratory crackles were noted on auscultation of
the chest. Four of 5 symptomatic patients required
hospitalization for further diagnostic evaluation
after their initial clinical assessment. Lung biopsy
was obtained by video-assisted thoracoscopic sur-
gery (VATS) in 4 patients and transbronchoscopic
lung biopsy (TBLB) in 2. The right upper lobe was
the site of biopsy in 3, left upper lobe in 2, and
right lower lobe in 1. OP was the primary
histopathologic finding in all 6 cases. Bronchoal-
veolar lavage with cell differential was performed
in 3 cases, none of which showed lymphocytic
predominance (lymphocyte count; 15%, 8%, and
3%), but instead were non-specific with alveolar
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OP in hematologic malignancies 165macrophages measuring greater than 80% in all 3
cases. Microbial cultures on lung biopsy specimens,
respiratory secretions, and bronchoalveolar lavage
did not yield any pathogens.Radiologic findings
Five patients had chest radiographs available for
current review from the time of their diagnostic
evaluation; 4 of these patients also had a CT scan.
One patient was referred to our institution after
diagnostic evaluation elsewhere and had no ima-
ging studies retrievable for our review. Chest
radiographs demonstrated patchy bilateral (2 pa-
tients) or diffuse (3 patients) parenchymal infil-
trates. CT scan of the chest revealed patchy
consolidative opacities (Fig. 1) in 2 patients and
diffuse ground-glass opacities (Fig. 2) in 2 patients.Figure 1 Computed tomography (CT) of organizing
pneumonia (OP) in a 60-year-old woman with acute
myelogenous leukemia. This image demonstrates patchy
infiltrates of consolidative and ground-glass character,
more severe on the left.
Figure 2 High-resolution CT of OP in a 49-year-old man
with myelodysplastic syndrome. This image reveals the
diffuse ground-glass opacities with vague nodularity.Treatment and outcome
Corticosteroid treatment was initiated in all but 1
patient (managed with observation only) with
radiologic and symptomatic resolution in all. Of
the 5 treated patients, all were given oral
prednisone as the initial therapy, with doses
ranging from 30 to 80mg per day (mean; 52mg
per day) and duration of therapy ranging from 3
weeks to 5 months. Four patients died, including 3
who died from non-respiratory causes including
progression of the underlying malignancy (Table 1).
Cause of death was unknown in 1 patient. Two
patients were alive more than a year after lung
biopsy, including the untreated patient.Discussion
OP occurring in patients with hematologic malig-
nancies may have multiple causes. Most of these
patients are exposed to chemotherapeutic agents
and radiotherapy, both of which have been asso-
ciated with OP.1 However, two of our patients had
no such exposure and OP may have been directly
related to the hematologic malignancy itself. OP
following BMT can be seen as the pulmonary
manifestation of GVHD.3,9,10 In our case series, 3
of the 6 patients had a history of BMTwhich may be
the likely etiology for the development of OP in
these 3 cases. One of these was a patient who had
undergone allogeneic BMTand demonstrated active
GVHD at the time of diagnosis of OP. OP, con-
strictive bronchiolitis (also called obliterative
bronchiolitis and bronchiolitis obliterans), diffuse
alveolar damage, and lymphocytic bronchitis/
bronchiolitis with interstitial pneumonitis may be
seen in the clinical scenario of hematologic
malignancy, GVHD, and new pulmonary infiltrates.
Biopsy is required to differentiate these processes
that can occur in the setting of BMT and GVHD.10
The overall incidence of OP is not known, and has
not been established in patients’ with hematologic
malignancy. In our series we reviewed 17,808
unique patients with hematologic malignancy,
2021 of whom had BMT, to find 6 patients in which
OP was the primary pathologic process without an
identifiable cause, e.g., infection. This implies OP
is a rare diagnosis with an estimated incidence in
our study of 34 per 100,000 patients with hemato-
logic malignancy. Our study indicates prior BMT
increases the incidence to an estimated 148 cases
per 100,000, but this is based on only 3 patients
with OP and prior BMT. It is likely the incidence
we report underestimates the true incidence of OP
in this population based upon several factors;
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OP in hematologic malignancies 167inclusion of only those patients with surgical or
bronchoscopic biopsy, the possibility of referral
bias, and the likelihood that most OP patients
treated with empiric corticosteroids will improve.
Despite the low incidence, OP should be con-
sidered in all patients with hematologic malignan-
cies who present with new onset of respiratory
symptoms. All but one of our patients presented
with systemic and respiratory complaints resulting
in hospitalization in 4 of them. Subacute onset of
cough, dyspnea, fever, and weight loss are common
manifestations of OP arising against a backdrop of
hematologic malignancy. These symptoms are,
however, non-specific and usually prompt a diag-
nostic evaluation for various etiologies including
opportunistic infections. Radiologic manifestations
of OP are also non-specific and typically include
patchy or nodular consolidative infiltrates.7 Infil-
trates can be unilateral, bilateral, peripheral or
central, and occasionally migrate over a period of
weeks to months. In the largest single study of OP
occurring in association with underlying malignan-
cies, Mokhtari et al.,4 demonstrated nodules or
masses in patients with solid organ tumors while
diffuse parenchymal infiltrates were more common
in patients with hematologic malignancies.4 Diffuse
bilateral infiltrates were present by conventional
radiographs or CT scan in half of our patients.
Although diffuse disease is linked to a more
aggressive course in some reports, all patients with
diffuse disease in our study responded to corticos-
teroid therapy.
Tissue biopsy is required for definitive diagnosis
of OP. TBLB can be helpful in establishing a
diagnosis of OP if the pathologic findings are
carefully correlated with clinical and radiologic
findings.11,12 Both bronchoscopic and surgical lung
biopsies were utilized to establish a diagnosis of OP
in our patients. Surgical lung biopsy is the most
common diagnostic method employed in previously
reported patients (Table 2).
The overlapping clinical and radiographic pre-
sentation makes differentiation of OP from infec-
tious etiologies challenging in immunosuppressed
patients. Given the demonstrated benefit of pre-
dnisone therapy in our patients, early use of lung
biopsy should be considered to distinguish OP from
other conditions.8 Recently, several reports have
highlighted the safety and efficacy of surgical and
bronchoscopic lung biopsy in patients with hema-
tologic malignancy and pulmonary infiltrates.8,13,14
Although diagnostic yield in this setting remains
suboptimal, (62% in a recent study of surgical lung
biopsy8), when a diagnosis is obtained, it results in
a therapeutic change in two-thirds of patients and
is associated with improved survival.8COP is considered a steroid responsive disease,
and treatment with prednisone 0.75mg/kg/day is
recommended with complete resolution of symp-
toms in greater than two-thirds of patients.2
Because as many as one-third of patients treated
for less than 3 months will relapse, recommended
duration of therapy is 6–12 months.2 All of our
patients were treated for less than 6 months,
perhaps reflecting concern for the possibility of
secondary infection in this immunosuppressed
group. Despite the short duration of therapy, none
of our patients had clinical or radiographic evi-
dence of relapse. Although overall mortality was
high at 1 year, none of our patients for whom a
cause of death was known died of a respiratory-rela-
ted condition. Review of the literature (Table 2)
supports our findings, with attributed respiratory
mortality in only 7 of 49 (14%) patients in which
causal mortality was reported. These data support
a favorable disease-specific prognosis, and illus-
trate the beneficial effect of therapy when a
diagnosis of OP is found in association with
hematologic malignancy.
In summary, awareness of the clinicoradiologic
presentation of OP in patients with hematologic
malignancy is the key to early diagnosis which
is confirmed by lung biopsy and is associated
with a good response to corticosteroid therapy.
Clinical presentation is non-specific and generally
includes respiratory and systemic symptoms. Find-
ings on chest radiography and CT are similarly
non-specific and include patchy or diffuse parench-
ymal infiltrates of consolidative or ground-glass
character. The presence of an underlying hemato-
logic malignancy should raise the possibility of OP
as a diagnostic possibility for lung infiltrates of
undetermined cause in such a patient. After
excluding the possibility of infection, a trial of
corticosteroid therapy may be warranted for these
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